Insights Into Breast Cancer
Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer (TNBC), and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease
Faculty Chair
Reshma Mahtani, DO
Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA
Faculty Chair
Jason Mouabbi, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Philip Lammers, MD
Baptist Cancer Center, Bartlett, TN, USA
Faculty Chair
Jason M. Mouabbi, MD
University of Texas MD Anderson Cancer Center, Houston, Texas, USA
More Information
- Tampa, FL
- Florida
More Information
- Scottsdale, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Indiana, Iowa, Michigan, Minnesota, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
More Information
- San Diego, CA
- California
More Information
- Seattle, WA
- Idaho, Montana, Northern California, Oregon, Washington, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of breast cancer
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained
- HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, and chemotherapies
- HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, and chemotherapies
- TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, and chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
